US · Healthcare · Medical Devices
EPS came in at -0.23 against a street estimate of -0.25 — a beat of 8.0%.
Analysts rate Orthopediatrics Corp a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $30.75.
CONFIDENT OrthoPediatrics delivered record third-quarter revenue, improving EBITDA and positive free cash flow, raised 2026 revenue guidance, and sees substantial Super Cycle upside ahead. Q3 FY26 U.S. revenue was $57.9 million; international revenue was $14.8 million, with strong EMEA performance partly offset by LatAm set-sales timing. Analysts pressed management on fourth-quarter cash flow, 2027 growth, and Super Cycle profitability. Management emphasized disciplined guidance, timing-related commission effects, and higher-margin, capital-efficient products. 2026-10-27…
Full summary in the app.
| Fund | Stake |
|---|---|
| Brown Advisory Holdings Inc | 6.43% |
| BlackRock Inc | 4.87% |
| BRAIDWELL LP | 4.21% |
| Granahan Investment Management Inc.. | 4.16% |
| Millennium Management LLC | 3.13% |
| Wellington Management Company LLP | 3.04% |
| Vanguard Capital Management, LLC | 2.89% |
| Soleus Capital Management, L.P. | 2.80% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $72,661, up from $61,250 in the third quarter of 2025, an increase of approximately 19%. • Nine-mo | 2026-10-28 |
| Reg FD disclosure · Q4 2026 OTHER NOTABLE POINTS • OrthoPediatrics Corp. filed a Form 8-K dated October 27, 2026. • The filing announces upcoming presentations by company execu | 2026-10-27 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was a record $72.7 million, up 19% from $61.2 million in Q3 2025. • Net loss improved to $5.9 million, | 2026-10-27 |
| Quarterly report · Q2 2026 HEADLINE NUMBERS • Second-quarter 2026 revenue was $70,508, up from $61,082 in the second quarter of 2025, an increase of approximately 15%. • Six-m | 2026-08-05 |
| Reg FD disclosure · Q3 2026 OTHER NOTABLE POINTS • OrthoPediatrics Corp. filed a Form 8-K on August 4, 2026, under Regulation FD. • Company executives plan to make several upco | 2026-08-04 |
| Results announced · Q3 2026 HEADLINE NUMBERS • Second-quarter 2026 revenue reached a record $70.5 million, up 15% from $61.1 million in the second quarter of 2025. • Adjusted E | 2026-08-04 |
| Shareholder vote results · Q2 2026 HEADLINE NUMBERS • OrthoPediatrics held its 2026 Annual Meeting of Stockholders on June 4, 2026. • Stockholders elected four director nominees to se | 2026-06-04 |
| Quarterly report · Q1 2026 HEADLINE NUMBERS • First-quarter 2026 revenue was $59,362, up from $52,411 in the first quarter of 2025, an increase of approximately 13%. • Gross p | 2026-05-01 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Orthopediatrics Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.